Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!
Anthony P. Mack, insider at Virpax Pharmaceuticals
Anthony P. Mack Insider Alerts

Get notified the next time Anthony P. Mack buys or sells Virpax Pharmaceuticals stock. Enter your email address below to get our daily insider buying and selling report.

Anthony P. Mack Insider Information

Anthony P. Mack has more than 25 years of experience in the pharmaceutical and finance industries. Prior to founding Virpax in 2016, Mr. Mack founded Scilex Pharmaceuticals and served as President and CEO until February 2018. Scilex was sold to a publicly traded company. Mr. Mack founded his first pharmaceutical company, ProSolus Pharmaceuticals, in 2009 where he served as President before selling the company to Mission Pharmacal in 2015. Mr. Mack has held high-level management positions with Purdue Pharma, Endo Pharmaceuticals, Novartis, and EKR Therapeutics. He has led training, marketing, and commercial distribution for billion-dollar pain management products and has forged key strategic alliances. Mr. Mack has served as Founder, Director, and Executive Officer of ProSolus Pharmaceuticals and Scilex Pharmaceuticals. Mr. Mack has utilized his skills and experience to implement corporate governance policies and overall business strategy by serving on executive boards. Mr. Mack holds an Executive MBA in Pharmaceutical and Healthcare Marketing from Saint Joseph’s University.

How old is Anthony P. Mack?

Mr. Mack is currently 59 years old. There are 3 older executives and no younger executives at Virpax Pharmaceuticals. The oldest executive at Virpax Pharmaceuticals is Mr. Gerald W. Bruce, Exec. VP of Commercial Operations, who is 64 years old. Learn More.

How do I contact Anthony P. Mack?

The corporate mailing address for Mr. Mack and other Virpax Pharmaceuticals executives is 1055 Westlakes Drive Suite 300, Berwyn PA, 19312. Virpax Pharmaceuticals can also be reached via phone at 610-727-4597 and via email at [email protected]

Has Anthony P. Mack been buying or selling shares of Virpax Pharmaceuticals?

During the past quarter, Anthony P. Mack has bought $100,249.00 of Virpax Pharmaceuticals stock. Most recently, on Thursday, November 18th, Anthony P. Mack bought 25,125 shares of Virpax Pharmaceuticals stock. The stock was acquired at an average cost of $3.99 per share, with a total value of $100,248.75.

Are insiders buying or selling shares of Virpax Pharmaceuticals?

In the last twelve months, Virpax Pharmaceuticals insiders bought shares 3 times. They purchased a total of 29,125 shares worth more than $116,252.75. The most recent insider tranaction occured on November, 22nd when Director Jerrold Sendrow bought 3,900 shares worth more than $15,288.00.

Information on this page was last updated on 11/22/2021.

Anthony P. Mack Insider Trading History at Virpax Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/18/2021Buy25,125$3.99$100,248.75View SEC Filing Icon  
See Full Table

Anthony P. Mack Buying and Selling Activity at Virpax Pharmaceuticals

This chart shows Anthony P Mack's buying and selling at Virpax Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Virpax Pharmaceuticals Company Overview

Virpax Pharmaceuticals logo
Virpax Pharmaceuticals, Inc., a preclinical stage biopharmaceutical company, develops and manufactures non-opioid and non-addictive pharmaceutical products using drug delivery systems for pain management. The company offers products, such as Epoladerm, a diclofenac metered-dose spray film for acute musculoskeletal pain; Probudur (LBL100), long-acting bupivacaine liposomal gel for postoperative pain management; OSF200 for chronic osteoarthritis of the knee; and NES100 (Envelta), an exogenous enkephalin intranasal spray for acute and chronic pain. It also develops PES200 for the management of post-traumatic stress disorder; and MMS019 high-density molecular masking spray to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2 (Covid-19). Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
Read More

Today's Range

Now: $3.76
Low: $3.74
High: $4.21

50 Day Range

MA: $4.50
Low: $3.76
High: $6.02

2 Week Range

Now: $3.76
Low: $3.70
High: $36.00

Volume

533,953 shs

Average Volume

2,270,449 shs

Market Capitalization

$44.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!